CN Patent

CN113100233B — 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用

Assigned to Dalian University of Technology · Expires 2022-02-08 · 4y expired

What this patent protects

本发明涉及芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用，本发明揭示了芳甲羟肟酸及其衍生化合物，在体外和体内对PDA均具有较强的抑制作用，并表现出高效的抵御植物病原真菌侵害植物宿主的作用，在作为抗菌剂以防治植物土传病害方面具有优越的应用前景。

USPTO Abstract

本发明涉及芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用，本发明揭示了芳甲羟肟酸及其衍生化合物，在体外和体内对PDA均具有较强的抑制作用，并表现出高效的抵御植物病原真菌侵害植物宿主的作用，在作为抗菌剂以防治植物土传病害方面具有优越的应用前景。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN113100233B
Jurisdiction: CN
Classification: —
Expires: 2022-02-08
Drug substance claim: No
Drug product claim: No
Assignee: Dalian University of Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.